Has Mark Hutto, MD received payments from drug or device companies?

Yes. Drug and device makers reported $11,547 in general payments to Mark Hutto, MD across 370 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mark Hutto, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mark Hutto, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mark Hutto, MD

Psychiatry · Atlanta, GANPI 1699844159

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (59.9%), other and education — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Neuronetics, Inc. at 39.6% of the total. 2025 is the largest year on record at $4,818, 2.2 times the $2,239 reported in 2019. Among psychiatry clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,547in general payments, 2019–2025

Across 370 payments — averaging $31.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Neuronetics, Inc.$5K
Johnson & Johnson$1K
AbbVie$840
Lundbeck LLC$804
Alkermes, Inc.$738
Otsuka America Pharmaceutical, Inc.$571
plus $3K from 18 others

What the payments were for

Food & beverage$6,92060%
Education$520%
Other$4,57540%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Neuronetics, Inc.	1	$4,575
Johnson & Johnson	42	$1,013
AbbVie(2 entities)	48	$840
Lundbeck LLC	56	$804
Alkermes, Inc.	36	$738
Otsuka America Pharmaceutical, Inc.	31	$571
Takeda Pharmaceuticals U.S.A., Inc.	32	$560
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	31	$483
Sunovion Pharmaceuticals Inc.	19	$418
Teva Pharmaceuticals USA, Inc.	19	$298
Neurocrine Biosciences, Inc.	9	$173
Indivior Inc.	5	$130
AstraZeneca	1	$125
Bausch Health US, LLC	6	$124
Vanda Pharmaceuticals Inc.	6	$121
E.r. Squibb & Sons, L.L.C.	5	$113
Eisai Inc.	2	$113
Ironshore Pharmaceuticals Inc.	5	$112
Shire North American Group Inc	6	$79
Corium, LLC	5	$76
Supernus Pharmaceuticals, Inc.	2	$34
Avanir Pharmaceuticals, Inc.	1	$20
Adlon Therapeutics L.p.	1	$13
Noven Therapeutics, LLC	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,547 in reported general payments places this provider in the 90th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia →

Medicare billing

Part B allowed, 2024

$13,566

Medicare patients

Services billed

144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Paliperidone ErPaliperidone	17	$2,764
Haloperidol Decanoate 100Haloperidol Decanoate	15	$550
Quetiapine Fumarate	19	$392
Divalproex Sodium	22	$296
Desvenlafaxine Succinate ErDesvenlafaxine Succinate	12	$159
Benztropine Mesylate	16	$159
Bupropion XlBupropion Hcl	13	$132
Trazodone Hcl	12	$98
Amlodipine Besylate	12	$19

Paid to pharmacies, not to this prescriber.

Other psychiatry in Atlanta

David PurselleAtlanta$307K
Michael BurkeAtlanta$217K
Bryon EvansAtlanta$211K
Kerry ResslerAtlanta$196K
Patricio Riva PosseAtlanta$122K
Ray HorwitzAtlanta$64K
Boadie DunlopAtlanta$61K
Zohaib HaqueAtlanta$49K
Raymond KotwickiAtlanta$44K
Joseph BergerAtlanta$24K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →